News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

OXIS International, Inc. (OXIS) Licenses Lead Compound To HaptoGuard Inc.; BXT-51072, Phase II Compound, To Be Developed For Cardiovascular Diseases


10/19/2005 5:09:18 PM

OXIS International, Inc. (OTCBB:OXIS) (Nuveau Marche:OXIS) today announced that a worldwide exclusive license agreement has been signed with HaptoGuard Inc. for BXT-51072 and related compounds for cardiovascular indications. HaptoGuard will seek to develop and commercialize OXIS' lead glutathione peroxidase mimic, BXT-51072, for indications ranging from acute coronary syndromes and atherosclerosis to stroke.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES